Expression of EGFRvIII in glioblastoma: Prognostic significance revisited

Neoplasia

Volumn 13, Issue 12, 2011, Pages 1113-1121

  Montano, Nicola ^a   Cenci, Tonia ^a   Martini, Maurizio ^a   D'Alessandris, Quintino Giorgio ^a   Pelacchi, Federica ^b   Ricci Vitiani, Lucia ^b   Maira, Giulio ^b   de Maria, Ruggero ^a   Larocca, Luigi Maria ^a   Pallini, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DEPLETION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84855441538     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.111338     Document Type: Article

References (43)

1. Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, and Jenkins RB (2001). PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93, 1246-1256.
2. Sugawa N, Ekstrand AJ, James CD, and Collins VP (1990). Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87, 86062-86066.
3. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, and Collins VP (1991). Genes for epidermal growth factor receptor, transforming growth factor receptor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51, 2164-2172.
4. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, and Bigner DS (1992). Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89, 2965-2969.
5. Frederick L, Wang XY, Eley G, and James CD (2000). Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60, 1383-1387.
6. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, and James CD (2004). Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63, 700-707.
7. Huang HS, Nagane M, Klingbeil CK, Lin H, Nishikawa R, Ji XD, Huang CM, Gill GN, Wiley HS, and Cavenee WK (1997). The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272, 2927-2935.
8. Gan HK, Kaye AH, and Luwor RB (2009). The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16, 748-754.
9. Feldkamp MM, Lala P, Lau N, Roncari L, and Guha A (1999). Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45, 1442-1453.
10. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, et al. (2003). Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63, 6962-6970.
11. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, and Aldape K (2005). Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11, 1462-1466.
12. Liu L, Bäcklund LM, Nilsson BR, Grandér D, Ichimura K, Goike HM, and Collins VP (2005). Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 83, 917-926.
13. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353, 2012-2024.
14. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, et al. (2007). Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25, 2288-2294.
15. Viana-Pereira M, Lopes JM, Little S, Milanezi F, Basto D, Pardal F, Jones C, and Reis RM (2008). Analysis of EGFR overexpression, EGFR gene amplification and the EGFRvIII mutation in Portuguese high-grade gliomas. Anticancer Res 28, 913-920.
16. Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, et al. (2008). Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26, 5603-5609.
17. van den Bent MJ, Brandes AA, Rampling R, Kouwenhoven MC, Kros JM, Carpentier AF, Clement PM, Frenay M, Campone M, Baurain JF, et al. (2009). Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC Brain Tumor Group Study 26034. J Clin Oncol 27, 1268-1274.
18. Reardon DA, Vredenburgh JJ, Desjardins A, Peters K, Gururangan S, Sampson JH, Marcello J, Herndon JE II, McLendon RE, Janney D, et al. (2010). Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96, 219-230.
19. Thiessen B, Stewart C, Tsao M, Kamel-Reid S, Schaiquevich P, Mason W, Easaw J, Belanger K, Forsyth P, McIntosh L, et al. (2010). A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol 65, 353-361.
20. Heimberger AB, Suki D, Yang D, Shi W, and Aldape K (2005). The natural history of EGFR and EGFRvIII in glioblastoma patients. J Transl Med 3, 38.
21. World Health Organization Classification of the Nervous System (4th ed.). (2007). DN Louis, H Ohgaki, OD Wiestler, and CW Cavenee (Eds). IARC Press, Lyon, France. pp. 33-49.
22. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, et al. (2008). Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14, 8205-8212.
23. Martini M, Pallini R, Luongo G, Cenci T, Lucantoni C, and Larocca LM (2008). Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int J Cancer 123, 2955-2960.
24. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, et al. (2008). Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 14, 488-493.
25. Ricci-Vitiani L, Pallini R, Larocca LM, Lombardi DG, Signore M, Pierconti F, Petrucci G, Montano N, Maira G, and De Maria R (2008). Mesenchymal differentiation of glioblastoma stem cells. Cell Death Diff 15, 1491-1498.
26. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403.
27. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C, and De Maria R (2006). Chemotherapy resistance of glioblastoma stem cells. Cell Death Diff 13, 1238-1241.
28. Nagane M, Levitzki A, Gazit A, Cavenee WK, and Huang HJ (1998). Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3 like proteases. Proc Natl Acad Sci USA 95, 5724-5729.
29. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, and Rak J (2008). Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumor cells. Nat Cell Biol 10, 619-624.
30. Piccirillo SG, Combi R, Cajola L, Patrizi A, Redaelli S, Bentivegna A, Baronchelli S, Maira G, Pollo B, Mangiola A, et al. (2009). Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28, 1807-1811.
31. Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L, Falini A, De Palma M, Bulfone A, Poliani PL, et al. (2010). Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumorinitiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 70, 7500-7513.
32. Wakimoto H, Aoyagi M, Nakayama T, Nagashima G, Yamamoto S, Tamaki M, and Hirakawa K (1996). Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer 77, 373-380.
33. Cadieux B, Ching TT, Van den Berg SR, and Costello JF (2006). Genomewide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 66, 8469-8476.
34. Yoshida Y, Nakada M, Harada T, Tanaka S, Furuta T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y, and Hamada J (2010). The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol 98, 41-47.
35. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, Mehta MP, and Gilbert MR (2008). Correlation ofO6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26, 4189-4199.
36. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352, 997-1003.
37. Li HF, Kim JS, and Waldman T (2009). Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4, 43.
38. Zhan M and Han ZC (2004). Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 19, 915-923.
39. Chu CT, Everiss KD, Wilstrand CJ, Batra SK, Kung HJ, and Bigner DD (1997). Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324, 855-861.
40. Johns TG, Perera RM, Vernes SC, Vitali AA, Cao DX, Cavenee WK, Scott AM, and Furnari FB (2007). The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13, 1911-1925.
41. Johns TG, Luwor RB, Murone C, Walker F, Weinstock J, Vitali AA, Perera RM, Jungbluth AA, Stockert E, Old LJ, et al. (2009). Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100, 15871-15876.
42. Luo J, Solimini NL, and Elledge SJ (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-827.
43. Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, and Nimsky C (2011). Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol 13, 1339-1348.